^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

retlirafusp alfa (SHR-1701)

i
Other names: SHR-1701, SHR1701, SHR 1701
Company:
Dong-A, Jiangsu Hengrui Pharma
Drug class:
PD-L1 inhibitor, TGF-β R2 kinase inhibitor
Related drugs:
15d
SHR-1701 Combined with SHR2554 and BP102 for MCRC (clinicaltrials.gov)
P2, N=20, Not yet recruiting, Fudan University
New P2 trial • Metastases
|
retlirafusp alfa (SHR-1701) • SHR-2554
2ms
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies (clinicaltrials.gov)
P1, N=13, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=345 --> 13 | Recruiting --> Terminated; Sponsor R&D strategy adjustment
Enrollment change • Trial termination • Metastases
|
Mekinist (trametinib) • Ameile (aumolertinib) • retlirafusp alfa (SHR-1701) • Ariely (adebrelimab)
2ms
Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma. (PubMed, Cancers (Basel))
While preclinical data have demonstrated the great anti-tumorigenic potential of TGF-β inhibitors, the underwhelming results of ongoing and completed clinical trials highlight the difficulty actualizing these benefits into clinical practice. This topical review will discuss the relevant preclinical and clinical findings for TGF-β inhibitors in HNSCC and will explore the potential role of patient stratification in the development of this therapeutic strategy.
Review • Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
bintrafusp alfa (M7824) • retlirafusp alfa (SHR-1701) • ficerafusp alfa (BCA101) • LY3200882 • dalantercept (ACE-041)
3ms
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer (clinicaltrials.gov)
P2/3, N=81, Terminated, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=896 --> 81 | Trial completion date: Dec 2027 --> Apr 2024 | Enrolling by invitation --> Terminated | Trial primary completion date: Jul 2027 --> Apr 2024; R&d strategy adjustment
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • retlirafusp alfa (SHR-1701)
5ms
Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors (clinicaltrials.gov)
P1/2, N=81, Completed, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Dec 2021 --> Mar 2024
Trial completion • Trial completion date • Trial primary completion date
|
retlirafusp alfa (SHR-1701)
9ms
Blocking EGR1/TGF-β1 and CD44s/STAT3 Crosstalk Inhibits Peritoneal Metastasis of Gastric Cancer. (PubMed, Int J Biol Sci)
The blocking effect of SHR-1701 on TGF-β1 was verified by inhibiting peritoneal metastases in xenografts. Collectively, the interplay of EGR1/TGF-β1/CD44s/STAT3 signaling between mesothelial cells and GC cells induces EMT and stemness phenotypes, offering potential as a therapeutic target for PM of GC.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • TGFB1 (Transforming Growth Factor Beta 1) • EGR1 (Early Growth Response 1)
|
CD44 expression
|
retlirafusp alfa (SHR-1701)
10ms
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (clinicaltrials.gov)
P3, N=737, Active, not recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification
|
capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701)
11ms
A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer (clinicaltrials.gov)
P1/2, N=56, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed | Trial completion date: Aug 2022 --> Feb 2023
Trial completion • Trial completion date • Combination therapy • Metastases
|
gemcitabine • albumin-bound paclitaxel • retlirafusp alfa (SHR-1701)
11ms
Long-lasting complete response to SHR-1701 plus famitinib in refractory advanced gallbladder cancer: A case report. (PubMed, Hum Vaccin Immunother)
Adverse events were limited and manageable. This is the first report of such a treatment regimen being applied in a clinical setting, suggesting that the SHR-1701 and famitinib combination may be a promising immunotherapeutic approach for patients with refractory advanced GBC.
Journal • Metastases
|
TGFB1 (Transforming Growth Factor Beta 1)
|
PD-L1 negative
|
retlirafusp alfa (SHR-1701) • famitinib (SHR 1020)
11ms
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas (clinicaltrials.gov)
P1/2, N=100, Recruiting, Chinese PLA General Hospital | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Mar 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
retlirafusp alfa (SHR-1701) • SHR-2554
1year
A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced non-small cell lung cancer (NSCLC) (ESMO Asia 2023)
Conclusions SHR-1701 showed encouraging antitumor activity in all three cohorts. The safety profile was tolerable.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
TGFB1 (Transforming Growth Factor Beta 1)
|
EGFR mutation
|
retlirafusp alfa (SHR-1701)
over1year
A phase II clinical trial of SHR-1701 combined with temozolomide for advanced melanoma (ESMO 2023)
No grade ≥ 4 TRAEs occurred. Conclusions SHR-1701 plus TMZ showed promising antitumor activity in advanced melanoma pts, and was generally well tolerated.
Clinical • P2 data • Metastases
|
PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
temozolomide • retlirafusp alfa (SHR-1701)
over1year
SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study (ESMO 2023)
Background The standard 1L therapies for mCRC involve a fluoropyrimidine with oxaliplatin and/or irinotecan, and a biologic agent. Median PFS was 10.3 months (95% CI, 8.3-13.7), and median OS was immature. Conclusions SHR-1701 in combination with BP102 and XELOX as 1L treatment provided a manageable safety profile and potent antitumor activity in pts with unresectable mCRC.
Clinical • P2/3 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
|
BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus) • TGFB1 (Transforming Growth Factor Beta 1)
|
BRAF mutation • RAS mutation
|
capecitabine • oxaliplatin • irinotecan • retlirafusp alfa (SHR-1701)
over1year
A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors (ESMO 2023)
No grade 4/5 TRAEs were reported. Table: 1026MO Efficacy outcomes Variables GC/GEJC (1L) GC/GEJC (≥2L) nsqNSCLC All (n=19) CPS≥5 (n=15) All (n=27) CPS≥5 (n=9) All (n=10) Best overall response, n (%) CR 0 0 1 (3.7) 1 (11.1) 0 PR 4 (21.1) 4 (26.7) 8 (29.6) 6 (66.7) 1 (10.0) SD 7 (36.8) 5 (33.3) 5 (18.5) 1 (11.1) 5 (50.0) PD 7 (36.8) 5 (33.3) 12 (44.4) 1 (11.1) 3 (30.0) NE 1 (5.3) 1 (6.7) 1 (3.7) 0 1 (10.0) ORR, % (95% CI) 21.1 (6.1, 45.6) 26.7 (7.8, 55.1) 33.3 (16.5, 54.0) 77.8 (40.0, 97.2) 10.0 (0.3, 44.5) DCR, % (95% CI) 57.9 (33.5-79.7) 60.0 (32.3, 83.7) 51.8 (32.0, 71.3) 88.9 (51.8, 99.7) 60.0 (26.2, 87.8) mPFS, months (95% CI) 4.1 (1.3-NR) 4.1 (1.4-NR) 4.0 (1.4-NR) 10.3 (1.3-NR) 6.2 (1.3-9.9) Conclusions SHR-1701 plus BEV showed encouraging antitumor activity with a favorable safety profile in pts with advanced GC/GEJC and nsqNSCLC.
Clinical • P1/2 data • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
HER-2 negative
|
Avastin (bevacizumab) • retlirafusp alfa (SHR-1701) • Airuituo (bevacizumab biosimilar)
over1year
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=100, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
retlirafusp alfa (SHR-1701) • SHR-2554
over1year
New P1/2 trial • Combination therapy
|
retlirafusp alfa (SHR-1701) • SHR-2554
over1year
A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC (clinicaltrials.gov)
P2, N=0, Withdrawn, Jiangsu HengRui Medicine Co., Ltd. | N=168 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal • Metastases
|
retlirafusp alfa (SHR-1701) • famitinib (SHR 1020)
over1year
Enrollment open • Metastases
|
temozolomide • retlirafusp alfa (SHR-1701)
over1year
A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC (clinicaltrials.gov)
P2, N=107, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Mar 2025 | Trial primary completion date: Mar 2023 --> Jul 2023
Enrollment closed • Trial completion date • Trial primary completion date
|
carboplatin • paclitaxel • retlirafusp alfa (SHR-1701)
over1year
Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. (ASCO 2023)
16 (100%) cHL pts had received prior anti-PD1/PD-L1 antibody therapy, and 15 ( 93.8%) prior epigenetic therapies, such as decitabine or chidamide. SHR-1701 combined with SHR2554 showed acceptable safety profile and encouraging antitumor activity in immunotherapy-pretreated cHL, establishing the foundation for further exploration. Clinical trial information: NCT04407741.
Clinical • P1 data • Metastases
|
TGFB1 (Transforming Growth Factor Beta 1)
|
decitabine • Epidaza (chidamide) • retlirafusp alfa (SHR-1701) • SHR-2554
almost2years
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas (clinicaltrials.gov)
P1/2, N=100, Recruiting, Chinese PLA General Hospital | Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Mar 2023
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
retlirafusp alfa (SHR-1701) • SHR-2554
2years
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. (PubMed, BMC Med)
SHR-1701 showed an acceptable safety profile and encouraging antitumor activity in pretreated advanced solid tumors, especially in gastric cancer, establishing the foundation for further exploration.
P1 data • Clinical Trial,Phase I • Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
retlirafusp alfa (SHR-1701)
2years
PRELIMINARY EFFICACY AND SAFETY OF FAMITINIB PLUS SHR-1701 IN ADVANCED SARCOMA: A SINGLE-CENTER, PHASE 2 TRIAL (CTOS 2022)
We investigated the safety and efficacy of famitinib, a tyrosine kinase inhibitor (TKI) of angiogenesis, combined with the bifunctional fusion protein SHR-1701 targeting PD-L1 and TGF-β in patients (Pts) with chemotherapy-refractory sarcoma. Pts were eligible if they were aged 12 years or older, and had histologically confirmed advanced or metastatic sarcomas; the presence of measurable disease according to RECIST 1.1; an ECOG performance status of 0-1; progressive disease after at least one line of adriamycin containing chemotherapy; MSI-H or TMB>5 or PD-L1≥1% except for alveolar soft-part sarcoma (ASPS) and undifferentiated pleomorphic sarcoma (UPS). Famitinib plus SHR-1701 has manageable toxicity and preliminary activity in pts with advanced sarcomas, warranting further investigation.
Clinical • P2 data
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
doxorubicin hydrochloride • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020)
over2years
SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for recurrent or metastatic cervical cancer: a clinical expansion cohort of phase 1 study. (PubMed, Clin Cancer Res)
SHR-1701 exhibits encouraging antitumor activity and controllable safety in patients with recurrent or metastatic cervical cancer after platinum-based regimens, might providing another treatment option for this population.
P1 data • Journal
|
PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
retlirafusp alfa (SHR-1701)
over2years
A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). (ASCO 2022)
SHR-1701 showed tolerable toxicity profile and promising antitumor activity in patients with RM-NPC who failed prior platinum-based chemotherapy.
Clinical • P1 data
|
TGFB1 (Transforming Growth Factor Beta 1)
|
retlirafusp alfa (SHR-1701)
over2years
Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy. (PubMed, BioDrugs)
Currently, a limited number of small molecular inhibitor and monoclonal antibody candidates that target TGF-β are in clinical development in combination with the following immune checkpoint inhibitors: SRK 181, an antibody inhibiting the activation of latent TGF-β1; NIS 793, a monoclonal antibody targeting TGF-β; and SHR 1701, a fusion protein consisting of an anti-PD-L1 monoclonal antibody fused with the extracellular domain of human TGF-β receptor II. Several small molecular inhibitors are also in development and are briefly reviewed: LY364947, a pyrazole-based small molecular inhibitor of the serine-threonine kinase activity of TGFβRI; SB-431542, an inhibitor targeting several TGF-β superfamily Type I activin receptor-like kinases as well as TGF-β1-induced nuclear Smad3 localization; and galunisertib, an oral small molecular inhibitor of the TGFβRI kinase. One of the most advanced agents in this area is bintrafusp alfa, a bifunctional fusion protein composed of the extracellular domain of TGF-β receptor II fused to a human IgG1 mAb blocking PD-L1. Bintrafusp alfa is currently in advanced clinical development and as an agent in this space with the most clinical experience, is a focused highlight of this review.
Review • Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • SMAD3 (SMAD Family Member 3)
|
bintrafusp alfa (M7824) • retlirafusp alfa (SHR-1701) • galunisertib (LY2157299) • linavonkibart (SRK-181) • nisevokitug (NIS793)
almost3years
Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. (PubMed, Cancer Commun (Lond))
Lung cancer patients with poor lymphocyte recovery and suffering from persistent lymphopenia after previous chemotherapy are resistant to anti-PD-1/PD-L1 antibodies but might be sensitive to second-generation agents such as SHR-1701.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TGFB1 (Transforming Growth Factor Beta 1)
|
CD8 expression • IFNG expression
|
bintrafusp alfa (M7824) • retlirafusp alfa (SHR-1701)
almost3years
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (clinicaltrials.gov)
P3, N=920, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
PD-L1 expression • HER-2 overexpression • HER-2 amplification
|
5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • retlirafusp alfa (SHR-1701)
almost3years
A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer (clinicaltrials.gov)
P3, N=561, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Clinical • New P3 trial • Combination therapy
|
EGFR (Epidermal growth factor receptor)
|
Avastin (bevacizumab) • cisplatin • carboplatin • pemetrexed • retlirafusp alfa (SHR-1701)
3years
MULAN: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (clinicaltrials.gov)
P2, N=319, Recruiting, Fudan University | Not yet recruiting --> Recruiting | N=170 --> 319
Enrollment open • Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • PGR positive
|
Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • fulvestrant • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020) • SHR-2554 • SHR7390 • Airui'en (rezvilutamide)
over3years
[VIRTUAL] SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, as first-line therapy for PD-L1+ advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study (ESMO 2021)
SHR-1701 shows encouraging anti-tumor activity in treatment-naive PD-L1+ advanced/metastatic NSCLC pts, compared with the reported historical data of ICI monotherapy. Pts with PD-L1 TPS ≥50% have superior ORR.
Clinical • P1 data
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TGFB1 (Transforming Growth Factor Beta 1)
|
ALK translocation • ALK negative
|
retlirafusp alfa (SHR-1701)
over3years
[VIRTUAL] SHR-1701, a novel bifunctional anti-PD-L1/TGF-βRII agent, for pretreated recurrent/refractory (r/r) gastric cancer (GC): Data from a first-in-human phase I study (ESMO 2021)
SHR-1701 showed encouraging antitumor activity and manageable safety profile in pretreated r/r GC pts. PD-L1 might be a prognostic factor for SHR-1701, which needs further investigation.
P1 data • PD(L)-1 Biomarker • IO biomarker
|
TGFB1 (Transforming Growth Factor Beta 1)
|
PD-L1 expression • PD-L1 overexpression
|
retlirafusp alfa (SHR-1701)
over3years
[VIRTUAL] SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for pretreated advanced cervical cancer: Data from a clinical expansion cohort of a phase I study (ESMO 2021)
Primary endpoint was ORR per RECIST v1.1. Totally, 32 eligible pts were recruited: squamous cell carcinoma, 100%; ≥2 metastasis sites, 68.8%; prior platinum-based chemotherapy, 87.5%; prior platinum-based chemotherapy plus bevacizumab, 12.5%; previous neoadjuvant or adjuvant therapy, 15.6%. SHR-1701 exhibits encouraging antitumor activity and controllable safety in pts with previously treated advanced cervical cancer after platinum-based regimens, might providing another treatment option for this population.
Clinical • P1 data
|
PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
Avastin (bevacizumab) • retlirafusp alfa (SHR-1701)
over3years
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (clinicaltrials.gov)
P3, N=920, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
New P3 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
PD-L1 expression • HER-2 overexpression • HER-2 amplification
|
5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • retlirafusp alfa (SHR-1701)
over3years
[VIRTUAL] Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors. (ASCO 2021)
SHR-1701 showed acceptable safety profile and encouraging antitumor activity in refractory solid tumors, establishing the foundation for further exploration.
Clinical • P1 data
|
TGFB1 (Transforming Growth Factor Beta 1)
|
MSI-H/dMMR
|
retlirafusp alfa (SHR-1701)
over3years
[VIRTUAL] SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study. (ASCO 2021)
SHR-1701 monotherapy shows a manageable safety profile and encouraging antitumor activity in advanced EGFR+ NSCLC pts after failure of at least 1L standard EGFR TKI . Further investigation of SHR-1701 combination therapy for EGFR+ NSCLC is warranted.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • TGFB1 (Transforming Growth Factor Beta 1)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
retlirafusp alfa (SHR-1701)
4years
Clinical • Enrollment open • Combination therapy
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
retlirafusp alfa (SHR-1701) • SHR-2554
over4years
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas (clinicaltrials.gov)
P1/2, N=100, Not yet recruiting, Chinese PLA General Hospital | Initiation date: Jun 2020 --> Sep 2020
Clinical • Trial initiation date • Combination therapy
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
retlirafusp alfa (SHR-1701) • SHR-2554
over4years
Clinical • New P1/2 trial • Combination therapy
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
retlirafusp alfa (SHR-1701) • SHR-2554
over4years
New P2 trial • BRCA Biomarker • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • PGR positive
|
everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • retlirafusp alfa (SHR-1701) • famitinib (SHR 1020) • SHR-2554 • SHR7390 • Airui'en (rezvilutamide)